Biotech Law 
Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function – Genetic Engineering News
Founded in 1997, Kibow Biotech specializes in research and development of … or obligation to update these forward-looking statements except as required by law.
Nigeria: Experts Task President Jonathan on Biosafety Bill – AllAfrica.com
Speaking at the meeting, Prof. Bamidele Solomon, Director General, National Biotechnology Development Agency noted that countries such as Ghana has approved its biosafety law setting out structured mechanism for the monitoring and regulation of GMOs.
Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function – Bradenton Herald
More information is available at http://www.clinicaltrials.gov, under Kibow Biotech Inc – (NCT 01450670 … to update these forward-looking statements except as required by law. For further information, contact:Natarajan Ranganathan, Ph.D …
Genmab 2011 Annual Report – MSN Money
About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the … such statements in relation to actual results, unless required by law.
T1D Exchange Announces Hire of Imran Nasrullah as First Head of Strategic Alliances – Business Wire
While at Massachusetts Biotech Council, Mr. Nasrullah led business development … Mayo Medical Ventures and the Dana Farber Cancer Institute. Mr. Nasrullah earned a law degree from Suffolk University Law School, a Master of Science degree in exercise …
T1D Exchange Announces Hire of Imran Nasrullah as First Head of Strategic Alliances – Genetic Engineering News
While at Massachusetts Biotech Council, Mr. Nasrullah led business development … Mayo Medical Ventures and the Dana Farber Cancer Institute. Mr. Nasrullah earned a law degree from Suffolk University Law School, a Master of Science degree …
La Barge Rejoins Ballard Spahr – Private Equity Hub
La Barge, of counsel, will focus on the representation of clients in the technology, biotechnology, and pharmaceutical … where he advised the company on corporate transactions, securities law, and corporate governance issues.
Slow, costly process stymies generic biotech drugs – The Guardian
“We don’t have that today.” The U.S. healthcare law in 2010 stipulated that regulators establish a process for approving lower-cost copies of biotech drugs – often referred to as “biosimilars” because they are not made from the same living cell … Continue reading
Analysis: Slow, costly process stymies generic biotech drugs – Reuters
“We don’t have that today.” The U.S. healthcare law in 2010 stipulated that regulators establish a process for approving lower-cost copies of biotech drugs – often referred to as “biosimilars” because they are not made from the same living cell … Continue reading
Generic Biotech Drugs Stymied By Slow, Costly Process – Huffington Post
“We don’t have that today.” The U.S. healthcare law in 2010 stipulated that regulators establish a process for approving lower-cost copies of biotech drugs – often referred to as “biosimilars” because they are not made from the same living cell … Continue reading
